On April 1, 2016, the Eisai Group’s gastrointestinal disease business built up over 60 years and the Ajinomoto Group’s gastrointestinal disease business with amino acid technologies at its core will be integrated to establish EA Pharma, a gastrointestinal specialty pharma with a full value chain including research and development, production and logistics, sales and marketing. EA Pharma will strive toward realizing an Enterprise Architecture that will create new innovation from the two companies’ combined knowledge.
